How framing scheme optimisation and smoking status impacts binding potential analysis in dynamic PET with [11C]ABP688
Cláudia Régio Brambilla, Jürgen Scheins, Lutz Tellmann, Ahlam Issa, Hans Herzog, N. Jon Shah, Irene Neuner, Christoph W. Lerche
9th February 2023
Based on a [11C]ABP688 PET study on healthy controls (HC) and a group of schizophrenic patients (balanced and unbalanced number of smokers), this work compared two framing schemes to find out if using a ‘Const Trues’ framing scheme could minimise quantification biases propagated into binding potential (BPND), the extent to which confounders, such as smoking status, have to be controlled for during studies, and what the consequences for data interpretation are.
Following analysis, the results showed that non-consistent BPND outcomes due to bias propagation influenced by the framing scheme choice can be minimised using a ‘Const Trues’ framing scheme. Furthermore, this framing scheme can also mitigate the effect of additional confounding factors, such as smoking status in schizophrenia, which affects the counts in the reconstructed frame.
In light of these findings, the researchers strongly recommend that future studies include an evaluation of the impact on smoking status in samples of schizophrenic patients and healthy groups prior to group analysis for other variables considered in the study. Similarly, in order to minimise biased results in PET bolus infusion studies, they also recommend an evaluation of the quantitative bias that propagates to the BPND when defining the framing scheme prior to the final quantification and results interpretation.
Origional publication: Impact of framing scheme optimization and smoking status on binding potential analysis in dynamic PET with [11C]ABP688